Condition: Cardiac Amyloidosis · Sponsor: University Hospital, Essen
Exploration of prognostic parameters in 18F-Florbetaben PET/MRI in patients with cardiac amyloidosis. The clinical endpoints are defined as occurence of major adverse cardiac events (MACE) in amyloidosis patients. Additionally, MACE outcome stratified by PET parameters will be evaluated and individual parameters of the imaging techniques will be compared to each other (PET, MRI or echocardiography).
This description comes directly from the study's public registry record.
David Kersting, MD, PhD · +492017232073 · david.kersting@uk-essen.de
Lukas Kessler, MD · +492017232073 · lukas.kessler@uk-essen.de
Always discuss trial participation with your own doctor first.
| Department of Nuclear medicine, University Hospital Essen | Essen, North Rhine-Westphalia, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07154381